Comera Life Sciences Holdings, Inc.
CMRA evidence brief
What we can confirm
- Market Cap:
- $3K
- Lead Asset:
- CLS-001
What it means
What to watch
Prepared research question
What matters most for CMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Tracking 1 pipeline candidate for Comera Life Sciences Holdings, Inc..
Run Comera Life Sciences Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Comera Life Sciences Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 1.4%
- Days to cover
- 0.8
- Shares short
- 281,553
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CMRA short interestGovernance
Frequently asked questions
Who is the CEO of Comera Life Sciences Holdings, Inc.?
Mr. Michael G. Campbell CPA is the chief executive officer of Comera Life Sciences Holdings, Inc. (CMRA).
Where is Comera Life Sciences Holdings, Inc. headquartered?
Comera Life Sciences Holdings, Inc. (CMRA) is headquartered in Woburn, MA, United States.
What therapeutic areas does Comera Life Sciences Holdings, Inc. focus on?
Comera Life Sciences Holdings, Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.